These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 9166099)

  • 1. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
    Nichols J; Foss F; Kuzel TM; LeMaistre CF; Platanias L; Ratain MJ; Rook A; Saleh M; Schwartz G
    Eur J Cancer; 1997 Jan; 33 Suppl 1():S34-6. PubMed ID: 9166099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2.
    LeMaistre CF; Saleh MN; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Nichols JC
    Blood; 1998 Jan; 91(2):399-405. PubMed ID: 9427692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
    Saleh MN; LeMaistre CF; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Sams MW; Nichols JC
    J Am Acad Dermatol; 1998 Jul; 39(1):63-73. PubMed ID: 9674399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
    Foss FM
    Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications.
    LeMaistre CF
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S37-40. PubMed ID: 11707862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
    Foss FM
    Clin Lymphoma; 2000 Sep; 1(2):110-6; discussion 117. PubMed ID: 11707818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with denileukin diftitox (ONTAK).
    Foss F
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S11-6. PubMed ID: 16516670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497.
    Kuzel TM; Li S; Eklund J; Foss F; Gascoyne R; Abramson N; Schwerkoske JF; Weller E; Horning SJ
    Leuk Lymphoma; 2007 Dec; 48(12):2397-402. PubMed ID: 17943599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-2 receptor-directed therapies for cutaneous lymphomas.
    Foss FM; Waldmann TA
    Hematol Oncol Clin North Am; 2003 Dec; 17(6):1449-58. PubMed ID: 14710895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational therapy for cutaneous T-cell lymphomas in the 1990s. Fact or fancy?
    Bunn PA
    Arch Dermatol; 1995 May; 131(5):603-5. PubMed ID: 7537952
    [No Abstract]   [Full Text] [Related]  

  • 11. Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study.
    Foss FM; Borkowski TA; Gilliom M; Stetler-Stevenson M; Jaffe ES; Figg WD; Tompkins A; Bastian A; Nylen P; Woodworth T
    Blood; 1994 Sep; 84(6):1765-74. PubMed ID: 8080984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of immunopathology in schistosomiasis by interleukin-2-targeted fusion toxin, DAB389IL-2. I. Studies of in vitro and in vivo efficacy.
    Ramadan MA; Gabr NS; Bacha P; Günzler V; Phillips SM
    Cell Immunol; 1995 Dec; 166(2):217-26. PubMed ID: 7497523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor.
    LeMaistre CF; Meneghetti C; Rosenblum M; Reuben J; Parker K; Shaw J; Deisseroth A; Woodworth T; Parkinson DR
    Blood; 1992 May; 79(10):2547-54. PubMed ID: 1586707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication.
    Foss FM; Bacha P; Osann KE; Demierre MF; Bell T; Kuzel T
    Clin Lymphoma; 2001 Mar; 1(4):298-302. PubMed ID: 11707845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas.
    Kuzel TM; Rosen ST; Gordon LI; Winter J; Samuelson E; Kaul K; Roenigk HH; Nylen P; Woodworth T
    Leuk Lymphoma; 1993 Nov; 11(5-6):369-77. PubMed ID: 8124209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preclinical and clinical researches of Denileukin Diftitox (Genetical Recombination) (Remitoro
    Shiiba H; Takechi A; Asakura S; Kawaguchi T; Sato M
    Nihon Yakurigaku Zasshi; 2022; 157(5):376-382. PubMed ID: 36047157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DAB486IL-2 fusion toxin in refractory rheumatoid arthritis.
    Sewell KL; Parker KC; Woodworth TG; Reuben J; Swartz W; Trentham DE
    Arthritis Rheum; 1993 Sep; 36(9):1223-33. PubMed ID: 8216416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denileukin diftitox: a concise clinical review.
    Eklund JW; Kuzel TM
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):33-8. PubMed ID: 15757436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denileukin diftitox.
    Figgitt DP; Lamb HM; Goa KL
    Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
    Chin KM; Foss FM
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):199-204. PubMed ID: 17229335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.